ARTICLE | Clinical News
Tezosentan (Ro 61-0612): Began Phase III trial
November 1, 1999 8:00 AM UTC
Actelion Ltd., Allschwil, Switzerland Product: Tezosentan (Ro 61-0612) Business: Cardiovascular Therapeutic category: Receptor antagonist Target: Endothelin receptors Description: Intravenous endothel...